Cefepime Dosing for Infected Arm Graft Site
For an adult with an infected arm graft site and normal renal function, administer cefepime 2 g IV every 12 hours for skin and soft tissue infections. 1
Standard Dosing Regimen
The FDA-approved dosing for moderate to severe uncomplicated skin and skin structure infections is 2 g IV every 12 hours for 10 days, administered as an infusion over approximately 30 minutes. 1 This recommendation comes directly from the drug label and represents the established standard of care.
Key Dosing Considerations
Renal Function Assessment
- If creatinine clearance >60 mL/min: Use standard dose of 2 g every 12 hours 1
- If creatinine clearance 30-60 mL/min: Reduce to 2 g every 24 hours 1
- If creatinine clearance 11-29 mL/min: Reduce to 1 g every 24 hours 1
- If creatinine clearance <11 mL/min: Reduce to 500 mg every 24 hours 1
Calculate creatinine clearance using the Cockcroft-Gault equation if only serum creatinine is available. 1
Infection Severity Factors
If the graft infection involves Pseudomonas aeruginosa or other resistant gram-negative organisms, consider escalating to 2 g every 8 hours. 2, 3 This higher frequency is specifically recommended when targeting pseudomonal infections. 1
For complicated infections with systemic signs (fever, hypotension, bacteremia), the more aggressive every-8-hour dosing provides better pharmacodynamic target attainment against less susceptible organisms. 4, 5
Alternative Administration Strategies
Continuous Infusion Option
Recent evidence suggests that continuous infusion of 4 g/day (after a 2 g loading dose) may optimize exposure while reducing neurotoxicity risk. 6 This approach achieved 96% pharmacodynamic target attainment for Enterobacterales and 93% for Pseudomonas with only 6.5% neurotoxicity. 6
However, this remains an off-label strategy requiring therapeutic drug monitoring and is best reserved for ICU settings or when intermittent dosing fails.
Extended Infusion
Administering the dose over 3 hours rather than 30 minutes may improve time above MIC, particularly for organisms with MIC values of 4-8 mg/L. 7 This is relevant if culture data reveal borderline susceptibility.
Critical Pitfalls to Avoid
Neurotoxicity risk: Cefepime accumulation causes encephalopathy, particularly with:
- Renal impairment (even mild dysfunction with CrCl 60-90 mL/min) 8
- Doses >6 g/day 8
- Delayed dose adjustment when renal function deteriorates 8
Monitor for confusion, myoclonus, seizures, or altered mental status. If neurotoxicity occurs, reduce dose immediately or switch antibiotics.
Augmented renal clearance: In young trauma patients or those with hyperdynamic states, standard dosing may be insufficient. 8 Consider therapeutic drug monitoring if available, targeting trough concentrations of 9-18 mg/L. 5
Duration of Therapy
Continue for 10 days total for uncomplicated skin/soft tissue infections. 1 Extend to 14 days if:
- Bacteremia is documented 9
- Slow clinical response occurs
- Prosthetic material is involved (graft material may require longer treatment)
Combination Therapy Considerations
Cefepime monotherapy is appropriate for most skin and soft tissue infections. 9 Add metronidazole only if anaerobic coverage is needed (e.g., contamination with bowel flora, foul-smelling discharge). 2, 1
For MRSA coverage (if suspected based on local epidemiology or prior cultures), add vancomycin 15-20 mg/kg every 8-12 hours. 9, 3
Monitoring Parameters
- Renal function every 2-3 days (adjust dose if CrCl drops)
- Clinical response by day 3-5 (defervescence, reduced erythema/drainage)
- Neurological status daily (especially if age >65 or any renal impairment)
- Culture results to confirm susceptibility and narrow therapy if possible
The 2 g every 12 hours regimen provides the optimal balance of efficacy and safety for most adult patients with infected graft sites and normal renal function, based on decades of clinical experience and FDA approval. 1